HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SKB BIO-B

343.800

+11.0003.31%

Volume:63.76K

Turnover:22.23M

Market Cap:78.04B

PE:-265.80

High:360.000

Open:332.800

Low:328.600

Close:332.800

Loading ...

Overview Company News Filings

BRIEF-Windward Bio Launches With $200 Million Series A Financing

Windward Bio: Orbimed, Novo Holdings, and Blue Owl Healthcare Opportunities Lead Series a Financing of $200M

THOMSON REUTERS

Windward Bio Launches With $200 Million Series a Financing to Develop Phase 2-Ready, Long-Acting Anti-Tslp Antibody With Best-in-Class Potential in Asthma and Copd

THOMSON REUTERS

Hbm Holdings - License Agreement Excludes Greater China and Several Southeast and West Asian Countries

THOMSON REUTERS

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical New Drug Application For Core Product Trastuzumab Botidotin Accepted

SKB Biopharma's NDA for Breast Cancer Drug Accepted by Chinese Regulator

MT Newswires Live

Sichuan Kelun-Biotech Biopharmaceutical - New Drug Application for Core Product Trastuzumab Botidotin Accepted by China Nmpa

THOMSON REUTERS

China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk

SKB Biopharmaceutical Gets China Marketing Nod for Nasopharyngeal Cancer

MT Newswires Live

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Anti-Pd-L1 Tagitanlimab Approved For Marketing By Nmpa Of China

Sichuan Kelun-Biotech Biopharmaceutical - Anti-Pd-L1 Tagitanlimab Approved for Marketing by Nmpa of China

THOMSON REUTERS

SKB Biopharma Avails of 300 Million Yuan Structured Deposits from China's Industrial Bank

MT Newswires Live

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe 2 Structured Deposits From Industrial Bank

Sichuan Kelun-Biotech Biopharmaceutical - to Subscribe 2 Structured Deposits From Industrial Bank of RMB170 Mln and RMB130 Mln

THOMSON REUTERS

Chinese Regulator Approves Sichuan Kelun-Biotech's Investigational New Drug Application for Tumor Drug

MT Newswires Live

Sichuan Kelun-Biotech Biopharmaceutical - Investigational New Drug Approval for Skb500 by Nmpa

THOMSON REUTERS

Stock Track | SKB BIO-B Soars 7.36% on NMPA Approval for Breast Cancer Drug

Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod Marketing Approval for Breast Cancer Drug; Share Up 5%

MT Newswires Live

Sichuan Kelun-Biotech Biopharmaceutical - Got Marketing Authorization in China for Trop2-Directed Antibody-Drug Conjugate

THOMSON REUTERS

Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing by Nmpa of China

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/06990/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":343.8,"timestamp":1746173305036,"preClose":332.8,"halted":0,"volume":63760,"delay":0,"floatShares":157000000,"shares":227000000,"eps":-1.29346774512524,"marketStatus":"Market Closed","change":11,"latestTime":"05-02 16:08:25","open":332.8,"high":360,"low":328.6,"amount":22230168,"amplitude":0.094351,"askPrice":343.8,"askSize":1600,"bidPrice":343,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-1.29346774512524,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":332.8,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.08178164965257703,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":157000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.293468,"volumeRatio":0.08178164965257703,"shares":227000000,"dividePrice":0,"high":360,"amplitude":0.094351,"preClose":332.8,"low":328.6,"week52Low":120.2,"pbRate":"21.95","psRate":"37.57","week52High":360,"institutionHeld":0,"latestPrice":343.8,"committee":-0.391304,"eps":-1.29346774512524,"divideRate":0,"volume":63760,"delay":0,"ttmEps":-1.29346774512524,"open":332.8,"prevYearClose":163.3,"prevWeekClose":293.8,"prevMonthClose":332.8,"prevQuarterClose":290.8,"fiveDayClose":308.2,"twentyDayClose":290.8,"sixtyDayClose":159.3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2502861152","title":"BRIEF-Windward Bio Launches With $200 Million Series A Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2502861152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502861152?lang=en_us&edition=fundamental","pubTime":"2025-01-10 22:09","pubTimestamp":1736518153,"startTime":"0","endTime":"0","summary":"Jan 10  - Windward Bio:   * WINDWARD BIO LAUNCHES WITH $200 MILLION SERIES A FINANCING TO DEVELOP PHASE 2-READY, LONG-ACTING ANTI-TSLP ANTIBODY WITH BEST-IN-CLASS POTENTIAL IN ASTHMA AND COPD   * WINDWARD BIO: ORBIMED, NOVO HOLDINGS, AND BLUE OWL HEALTHCARE OPPORTUNITIES LEAD SERIES A FINANCING OF $200MSource text:   ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","02142","BK1583","LU0196878994.USD","BK1161","BK1574"],"gpt_icon":0},{"id":"2502866038","title":"Windward Bio: Orbimed, Novo Holdings, and Blue Owl Healthcare Opportunities Lead Series a Financing of $200M","url":"https://stock-news.laohu8.com/highlight/detail?id=2502866038","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502866038?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:45","pubTimestamp":1736516755,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA6TWNTV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2502661068","title":"Windward Bio Launches With $200 Million Series a Financing to Develop Phase 2-Ready, Long-Acting Anti-Tslp Antibody With Best-in-Class Potential in Asthma and Copd","url":"https://stock-news.laohu8.com/highlight/detail?id=2502661068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502661068?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:45","pubTimestamp":1736516755,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA6TWNTV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","BK1574","06990","BK1583","BK1161","02142"],"gpt_icon":0},{"id":"2502682908","title":"Hbm Holdings - License Agreement Excludes Greater China and Several Southeast and West Asian Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2502682908","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502682908?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nFWN3O60IB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02142","BK1574","BK1583","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2501850784","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical New Drug Application For Core Product Trastuzumab Botidotin Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=2501850784","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501850784?lang=en_us&edition=fundamental","pubTime":"2025-01-08 00:24","pubTimestamp":1736267089,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical New Drug Application For Core Product Trastuzumab Botidotin AcceptedJan 7  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:NEW DRUG APPLICATION FOR CORE PRODUCT TRASTUZUMAB BOTIDOTIN ACCEPTED BY CHINA NMPAFurther company coverage: 6990.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O30N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2501270463","title":"SKB Biopharma's NDA for Breast Cancer Drug Accepted by Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2501270463","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501270463?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:07","pubTimestamp":1736251629,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical's  new drug application  for trastuzumab botidotin was accepted by China's National Medical Products Administration, a Tuesday bourse filing said.The product is indicated for the treatment of adult patients with HER2 positive unresectable or metastatic breast cancer who have received at least one prior anti-HER2 therapy, according to the biopharmaceutical company.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2501279029","title":"Sichuan Kelun-Biotech Biopharmaceutical - New Drug Application for Core Product Trastuzumab Botidotin Accepted by China Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2501279029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501279029?lang=en_us&edition=fundamental","pubTime":"2025-01-07 18:55","pubTimestamp":1736247312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O30N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2501292221","title":"China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2501292221","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501292221?lang=en_us&edition=fundamental","pubTime":"2025-01-07 16:23","pubTimestamp":1736238180,"startTime":"0","endTime":"0","summary":"0822 GMT - China's healthcare sector will likely get a significant boost from national policies in 1Q, Citi analysts write in a note. This year marks the start of the most positive structural change in the industry, as it will be the first time that China's public healthcare system is able to include commercial insurance providers as significant payers, they say. The brokerage recommends buying shares in companies that will be direct beneficiaries of the reform. These include pharmaceutical and biopharmaceutical firms, pharmaceutical distributors and medical device companies. Citi's top picks include Jiangsu Hengrui Medicine, Hansoh Pharmaceutical, SSY Group, Akeso, Sichuan Kelun-Biotech Biopharmaceutical, Mindray Medical, Sinopharm Group, WuXi AppTec, Wuxi Biologics and Gushengtang. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","LU0348825331.USD","LU2460026573.USD","LU0979878070.USD","02269","LU0348735423.USD","01099","LU0052750758.USD","BK1583","LU0140636845.USD","LU0359202008.SGD","LU1328615791.USD","LU0516422440.USD","600276","LU1242518857.USD","BK0196","BK4137","LU0516422952.EUR","LU0348784397.USD","LU0516423174.USD","LU0640798160.USD","BK1610","LU0196878994.USD","LU0405327148.USD","02273","BK1574","09926","BK0012","LU0326950275.SGD","LU0359201612.USD","BK1589","BK1219","LU0856984785.SGD","HCSG","BK1191","603259","06990","LU0819121731.USD","LU0039217434.USD","BK1576","LU1064131003.USD","LU0588546209.SGD","IE00B543WZ88.USD","03692","LU0456846285.SGD","SHTDY","LU0516422366.SGD","LU1997245094.SGD","BK0188","LU1880383366.USD"],"gpt_icon":0},{"id":"2500914427","title":"SKB Biopharmaceutical Gets China Marketing Nod for Nasopharyngeal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2500914427","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500914427?lang=en_us&edition=fundamental","pubTime":"2025-01-02 16:38","pubTimestamp":1735807112,"startTime":"0","endTime":"0","summary":"China's medical products administrator granted Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) marketing approval for a drug for recurrent or metastatic nasopharyngeal cancer, according to a Tuesda","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2495667952","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Anti-Pd-L1 Tagitanlimab Approved For Marketing By Nmpa Of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2495667952","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495667952?lang=en_us&edition=fundamental","pubTime":"2024-12-31 18:33","pubTimestamp":1735641194,"startTime":"0","endTime":"0","summary":"Dec 31 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * ANTI-PD-L1 TAGITANLIMAB APPROVED FOR MARKETING BY NMPA OF CHINAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Anti-Pd-L1 Tagitanlimab Approved For Marketing By Nmpa Of China","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2495166491","title":"Sichuan Kelun-Biotech Biopharmaceutical -  Anti-Pd-L1 Tagitanlimab Approved for Marketing by Nmpa of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2495166491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495166491?lang=en_us&edition=fundamental","pubTime":"2024-12-31 17:56","pubTimestamp":1735638999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241231:nFWN3NV0L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2492922846","title":"SKB Biopharma Avails of 300 Million Yuan Structured Deposits from China's Industrial Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2492922846","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492922846?lang=en_us&edition=fundamental","pubTime":"2024-12-18 14:04","pubTimestamp":1734501852,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  availed of two structured deposits from Industrial Bank  worth a total of 300 million yuan on Tuesday, according to a same-day filing with the Hong Kong exchange.The 170 million yuan deposit has a 97-day term set to mature March 25, 2025. It has an expected annualized floating rate of return of 1.3% or 2.5% per annum, the filing said.The 130 million yuan deposit has a 189-day term maturing June 25, 2025 and an expected annualized floating rate of return of 1.5% or 2.5% per annum, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","LU1781817850.SGD","LU0572939691.SGD","LU1580142542.USD","LU1328615791.USD","06990","BK1161","BK0187","LU0196878994.USD","LU0264606111.USD","BK0015","BK0028","LU0572940350.SGD","BK0278","LU0821914370.USD","BK0012","601166","BK0188","LU1048596156.SGD"],"gpt_icon":0},{"id":"2492296932","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe 2 Structured Deposits From Industrial Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2492296932","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492296932?lang=en_us&edition=fundamental","pubTime":"2024-12-17 23:15","pubTimestamp":1734448522,"startTime":"0","endTime":"0","summary":"Dec 17 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * TO SUBSCRIBE 2 STRUCTURED DEPOSITS FROM INDUSTRIAL BANK OF RMB170 MILLION AND RMB130 MILLION Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2492966692","title":"Sichuan Kelun-Biotech Biopharmaceutical - to Subscribe 2 Structured Deposits From Industrial Bank of RMB170 Mln and RMB130 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2492966692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492966692?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:57","pubTimestamp":1734447447,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nFWN3NI0IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2488316881","title":"Chinese Regulator Approves Sichuan Kelun-Biotech's Investigational New Drug Application for Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2488316881","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488316881?lang=en_us&edition=fundamental","pubTime":"2024-12-04 18:01","pubTimestamp":1733306475,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  received a clinical trial notice approving the investigational new drug application for SKB500 from China's National Medical Products Administration, a Wednesday bourse filing said.SKB500 is intended for the treatment of advanced solid tumors, according to the biopharmaceutical company.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2488159787","title":"Sichuan Kelun-Biotech Biopharmaceutical - Investigational New Drug Approval for Skb500 by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2488159787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488159787?lang=en_us&edition=fundamental","pubTime":"2024-12-04 16:43","pubTimestamp":1733301832,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N412T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"1136371661","title":"Stock Track | SKB BIO-B Soars 7.36% on NMPA Approval for Breast Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1136371661","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136371661?lang=en_us&edition=fundamental","pubTime":"2024-11-27 14:32","pubTimestamp":1732689154,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  saw its shares surge 7.36% in the intraday session on Wednesday, outperforming the broader market. The rally was fueled by the company receiving marketing authorization from China's National Medical Products Administration  for its breast cancer drug.The approved drug, sacituzumab tirumotecan , is designed to treat advanced or metastatic triple-negative breast cancer  in adult patients who have already undergone at least two prior systemic therapies, incl","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | SKB BIO-B Soars 7.36% on NMPA Approval for Breast Cancer Drug","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06990"],"gpt_icon":0},{"id":"2486147897","title":"Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod Marketing Approval for Breast Cancer Drug; Share Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486147897","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486147897?lang=en_us&edition=fundamental","pubTime":"2024-11-27 14:28","pubTimestamp":1732688887,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  said China's National Medical Products Administration  gave a marketing authorization for its breast cancer drug, according to a Wednesday filing with the Hong Kong bourse.The drug is designed for adults with advanced or metastatic triple-negative breast cancer  that cannot be surgically removed. It targets TROP2 using the antibody-drug conjugate sacituzumab tirumotecan , intended for patients who have already undergone at least two systemic treatments, including one for advanced or metastatic.The pharmaceutical company's stocks have increased by 5% in recent trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2486847893","title":"Sichuan Kelun-Biotech Biopharmaceutical - Got Marketing Authorization in China for Trop2-Directed Antibody-Drug Conjugate","url":"https://stock-news.laohu8.com/highlight/detail?id=2486847893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486847893?lang=en_us&edition=fundamental","pubTime":"2024-11-27 12:07","pubTimestamp":1732680430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MX0RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2486893841","title":"Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing by Nmpa of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2486893841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486893841?lang=en_us&edition=fundamental","pubTime":"2024-11-27 12:06","pubTimestamp":1732680380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MX14K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post Market","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"Post Market","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744732800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-05-02","current":-274.570331,"percent":0,"low":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"high":-21.029201,"avg":-100.2239,"sd":64.780777,"marketCap":78134738400},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200},{"date":"2025-04-25","current":-235.137362,"twenty":-160.624501,"median":-68.953584,"eighty":-45.131919,"marketCap":66771338400},{"date":"2025-05-02","current":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"marketCap":78134738400}],"updateTime":1746309955332}}}